IVVD
Invivyd, Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Mar 5 ▲ Invivyd reported strong financial and clinical progress, with Q4 202…
- Mar 5 ▲ Invivyd reported strong Q4 and full-year 2025 financial results with…
- Apr 9 Invivyd announced progress in its Phase 3 DECLARATION study for VYD2…
- May 14 Invivyd reported Q1 2026 PEMGARDA net product revenue of $13.7M (+22…
- Jul 6 ▼ Invivyd (IVVD) announced receipt of a 12-month advanced notice of EU…
- Aug 17 to Aug 18 ▼ 2 days of insider sells: $177.1K by 5 insiders, avg $0.7766
- Sep 1 Invivyd appointed Chairman Marc Elia as CEO, replacing the CFO who h…
- Sep 29 ▲ Invivyd announced positive topline results from the LIBERTY Phase 3…
- Oct 14 Trial readout: Results Pending: COVID-19 mRNA vaccine (Phase 3), Complete…
- Nov 3 Activist stake: Invivyd Reports Inducement Grants Under Nasdaq Listing Rul…
- Nov 16 New report: subscribers see the details Unlock
- Nov 16 New catalyst: subscribers see the details Unlock
Signal stack
Where each data set points today.
- InsidersBEARISH
5 insiders sold $177.1K.
- InstitutionsBULLISH
Q3 2026: 18 added (0 new), 9 trimmed or exited.
- AnalystsBULLISH
8 of 9 rate it Buy or better.
- Short sellersSTEADY
Short interest −2.3% to 36.20M shares. 9.7 days to cover, ≈12.3% of shares.
- TrendDOWNTREND
25% below its 50-day average.
- SocialQUIET
No Reddit mentions this week. Last mention Nov 7.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| Qube Research & Technologies Ltd | TRIM | $1.6M |
| UBS Group AG | ADD | $694.1K |
| JPMORGAN CHASE & CO | DOUBLED | $386.6K |
| BARCLAYS PLC | DOUBLED | $201.3K |
| RHUMBLINE ADVISERS | ADD | $172.7K |
| Vanguard Global Advisers, LLC | ADD | $94.3K |
| Quantinno Capital Management LP | DOUBLED | $85.9K |
| BNP PARIBAS FINANCIAL MARKETS | ADD | $67.4K |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
9 analysts| Date | Firm | Rating |
|---|---|---|
| Sep 14, 2026 | BTIG REITERATE | Buy |
| Aug 27, 2026 | Cantor Fitzgerald REITERATE | Overweight |
| Jul 7, 2026 | BTIG REITERATE | Buy |
| Jun 15, 2026 | HC Wainwright & Co. REITERATE | Buy |
| Jun 9, 2026 | BTIG REITERATE | Buy |
| Jun 1, 2026 | BTIG REITERATE | Buy |
Washington
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Sheffield Ian Director Aug 31, 2026 | AWARD | 100,000 sh |
Elia Marc Chief Executive Officer Aug 30, 2026 | AWARD | 10,700,000 sh |
Allen Robert D. III Chief Scientific Officer Aug 18, 2026 | SELL | $14.4K |
Duke William E. Chief Financial Officer Aug 18, 2026 | SELL | $15.5K |
Andersen Jill Chief Legal Officer, Secretary Aug 18, 2026 | SELL | $25.9K |
Lee Timothy Edward Chief Commercial Officer Aug 18, 2026 | SELL | $15.5K |
Green Julie Chief Human Resources Officer Aug 18, 2026 | SELL | $15.5K |
Allen Robert D. III Chief Scientific Officer Aug 17, 2026 | SELL | $14.9K |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026SecBot reports
11 filings · 8 press releases · 2 bullish · 1 bearish · 3 mixed · 5 neutral- NEUTRAL PRESS-RELEASENov 16, 2026
Invivyd reported Q3 2026 PEMGARDA net product revenue of $15.4M, up 18% YoY from $13.1M, but net loss widened to $33.5M from $10.5M due to higher R&D and SG&A spend. The key catalyst is the imminent DECLARATION Phase 3 interim data readout for VYD2311, which will determine the path to a BLA under…
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL PRESS RELEASENov 3, 2026
Invivyd granted 175,000 stock options to seven new non-executive employees as a material…
This is a routine inducement grant for new hires with no immediate trading implications. Monitor future filings for any larger equity grants or changes in insider ownership patterns.
- BULLISH 8-KSep 29, 2026
Invivyd announced positive topline results from the LIBERTY Phase 3 study, showing VYD2311 met all…
The DECLARATION topline safety and immunogenicity data expected in October 2026 is the next major catalyst. If positive, it could support the BLA submission for Accelerated Approval. Monitor for any…
- MIXED INST-CLUSTERSep 22, 2026
Institutional activity in IVVD during 2026-Q2 was mixed: 19 buyers added $1.9M in new holdings…
The heavy selling by Driehaus, State Street, and Millennium suggests a loss of conviction among large holders, while Citadel and Morgan Stanley's accumulation provides a counterweight. Monitor…
All IVVD filing & press-release reports (19)
- PRESS-RELEASE reportNov 16, 2026
- PRESS-RELEASE reportNov 3, 2026
- 8-K reportSep 29, 2026
- INST-CLUSTER reportSep 22, 2026
- 8-K reportSep 1, 2026
- 144 reportAug 17, 2026
- 8-K reportJul 6, 2026
- PRESS-RELEASE reportJun 16, 2026
- INST-CLUSTER reportJun 11, 2026
- PRESS-RELEASE reportJun 9, 2026
- PRESS-RELEASE reportJun 1, 2026
- 8-K reportMay 14, 2026
- PRESS-RELEASE reportMay 14, 2026
- 8-K reportApr 9, 2026
- PRESS-RELEASE reportApr 9, 2026
- PRESS-RELEASE reportApr 7, 2026
- 8-K reportMar 5, 2026
- PRESS-RELEASE reportMar 5, 2026
- PRESS-RELEASE reportMar 2, 2026